Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.16% $0.902
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 65.64 mill |
EPS: | -1.400 |
P/E: | -0.640 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 72.80 mill |
Avg Daily Volume: | 0.686 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.640 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.11x |
Company: PE -0.640 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.260 (39.77%) $0.359 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 0.834 - 0.970 ( +/- 7.54%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-15 | Schiller Mark C. | Sell | 0 | Common Stock |
2024-01-15 | Schiller Mark C. | Sell | 165 000 | Employee Stock Option (right to buy) |
2024-01-15 | Schiller Mark C. | Sell | 250 000 | Employee Stock Option (right to buy) |
2024-01-07 | Belsky Marc | Buy | 295 000 | Employee Stock Option (right to buy) |
2024-01-07 | Mordwinkin Nicholas Michael | Buy | 275 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
-14.31 |
Last 100 transactions |
Buy: 7 465 931 | Sell: 10 295 837 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.902 (-0.16% ) |
Volume | 1.145 mill |
Avg. Vol. | 0.686 mill |
% of Avg. Vol | 167.01 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.